The treatment plan for NSCLC now includes certain blood- and tissue-related biomarkers [100,101,102] such as tumor mutation burden [103], tumor infiltrating lymphocytes [104], and soluble PD-L1 [105] and other clinical factors such as neutrophil to lymphocyte ratio [106] and lung immune prognostic index [107]. Here, CD274 is linked to neoplasm.